{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.79","upperLimit":"8.25","value":"8.1"},{"groupId":"OG001","lowerLimit":"38.47","upperLimit":"56.18","value":"44.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"195"}],"units":"Participants"}],"description":"Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up","dispersionType":"95% Confidence Interval","groups":[{"description":"An anti-CD20 monoclonal antibody\n\nofatumumab: The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.\n\nWeek 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)","id":"OG000","title":"Ofatumumab (Arm A)"},{"description":"A Bruton Tyrosine Kinase Inhibitor\n\nibrutinib: ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity","id":"OG001","title":"Ibrutinib (Arm B)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From study initiation to study closure, including up to 6 years of study follow-up","title":"Progression Free Survival (PFS) by Investigator With up to 6 Years of Study Follow-up","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"months"}